share_log

康哲藥業：翌日披露報表

CMS: Next Day Disclosure Return

香港交易所 ·  Apr 2 07:52
Summary by Moomoo AI
康哲藥業控股有限公司（CMS）於2024年4月2日進行了股份購回活動，購回股份總數為2,100,000股，佔其已發行股份的0.0856%。購回的平均價格介於HKD 7.26至HKD 7.67之間，總支付金額為HKD 15,642,180。該次股份購回並未導致公司已發行股本的變動，結存股份數目維持在2,451,988,512股。根據香港聯合交易所有限公司證券上市規則，公司已完成相關的披露要求，並確認所有交易均符合規定，購回報告已正式提交。
康哲藥業控股有限公司（CMS）於2024年4月2日進行了股份購回活動，購回股份總數為2,100,000股，佔其已發行股份的0.0856%。購回的平均價格介於HKD 7.26至HKD 7.67之間，總支付金額為HKD 15,642,180。該次股份購回並未導致公司已發行股本的變動，結存股份數目維持在2,451,988,512股。根據香港聯合交易所有限公司證券上市規則，公司已完成相關的披露要求，並確認所有交易均符合規定，購回報告已正式提交。
On April 2, 2024, Conge Pharmaceutical Holdings Limited (CMS) conducted a share repurchase activity for a total of 2,100,000 shares representing 0.0856% of its issued shares. The average buy-back price is between HKD 7.26 and HKD 7.67, with a total payout of HKD 15,642,180. The share buyback did not result in any change in the issued share capital of the company and the number of shares outstanding remained at 2,451,988,512 shares. Pursuant to the Listing Rules of the Hong Kong Stock Exchange Limited, the Company has completed the relevant disclosure requirements and has confirmed that all transactions are in compliance. The Return Report has been formally submitted.
On April 2, 2024, Conge Pharmaceutical Holdings Limited (CMS) conducted a share repurchase activity for a total of 2,100,000 shares representing 0.0856% of its issued shares. The average buy-back price is between HKD 7.26 and HKD 7.67, with a total payout of HKD 15,642,180. The share buyback did not result in any change in the issued share capital of the company and the number of shares outstanding remained at 2,451,988,512 shares. Pursuant to the Listing Rules of the Hong Kong Stock Exchange Limited, the Company has completed the relevant disclosure requirements and has confirmed that all transactions are in compliance. The Return Report has been formally submitted.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more